Literature DB >> 16815536

Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer.

Eric L Eisenhauer1, Michael I D'Angelica, Nadeem R Abu-Rustum, Yukio Sonoda, William R Jarnagin, Richard R Barakat, Dennis S Chi.   

Abstract

OBJECTIVES: Diaphragm peritonectomy or resection is an effective way to cytoreduce diaphragm disease but frequently results in sympathetic pleural effusions. Our objective was to determine the incidence and management of effusions that developed after diaphragm surgery in patients with advanced mullerian cancer.
METHODS: We reviewed the records of all patients with stage IIIC-IV epithelial ovarian, fallopian tube, or peritoneal cancer who had diaphragm peritonectomy or resection as part of optimal primary cytoreduction at our institution from 2000-2003. All patients had preoperative and serial postoperative chest X-rays to detect and follow pleural effusions. Factors evaluated included the presence and size of preoperative and postoperative effusions, their laterality, and subsequent need for thoracentesis and/or chest tube placement for symptomatic effusions.
RESULTS: Of the 215 patients who had primary cytoreduction during the study period, 59 (27%) underwent diaphragm peritonectomy or resection. In addition to standard cytoreduction, 31 (53%) of these 59 patients had diaphragm surgery alone, while 28 (47%) had diaphragm surgery in combination with other upper abdominal resections. Laterality of diaphragm surgery was as follows: right only, 43 (73%); left only, 2 (3%); and bilateral, 14 (24%). Intraoperative chest tubes were placed in 7 (12%) patients. In the remaining 12 patients with preoperative effusions, postoperative effusions on the same side as the diaphragm surgery increased in 6 patients (50%), and 3 patients (25%) required postoperative thoracentesis or chest tube. In the remaining 40 patients without preoperative effusions, ipsilateral effusions developed in 24 patients (60%), and 5 patients (13%) required postoperative chest tubes. The overall rate of new or increased ipsilateral effusions was 58%; the overall rate of postoperative thoracentesis or chest tube placement was 15%. In 75% of the patients, thoracentesis or chest tubes were placed within 5 days of surgery (median, 3 days; range, 2-24).
CONCLUSIONS: More than half of patients developed ipsilateral pleural effusions after diaphragm peritonectomy for cytoreduction. Most were managed conservatively without requiring a chest tube or thoracentesis. The incidence of symptomatic effusions was not high enough to recommend routine chest tube placement at the time of diaphragm peritonectomy or resection.

Entities:  

Mesh:

Year:  2006        PMID: 16815536     DOI: 10.1016/j.ygyno.2006.05.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2015-05-31       Impact factor: 5.482

2.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; William J Hoskins; Pavani R Pingle; Mario M M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

3.  Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.

Authors:  P Cascales Campos; L A Martinez Insfran; D Wallace; J Gil; E Gil; A Gonzalez Gil; J Martínez; J L Alonso Romero; R Gonzalez Sanchez; P Parrilla
Journal:  Clin Transl Oncol       Date:  2019-08-07       Impact factor: 3.405

Review 4.  Narrative review of liver mobilization, diaphragm peritonectomy, full-thickness diaphragm resection, and reconstruction.

Authors:  Wonkyo Shin; Jaehee Mun; Sang-Yoon Park; Myong Cheol Lim
Journal:  Gland Surg       Date:  2021-03

5.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.

Authors:  Sean C Dowdy; Ralitsa T Loewen; Giovanni Aletti; Simone S Feitoza; William Cliby
Journal:  Gynecol Oncol       Date:  2008-04-01       Impact factor: 5.482

6.  Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer.

Authors:  Myong Cheol Lim; Sokbom Kang; Yong Jung Song; Sae Hyun Park; Sang-Yoon Park
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

7.  Incidental events of diaphragmatic surgery in 82 patients with advanced ovarian, primary peritoneal and fallopian tubal cancer.

Authors:  Fumitoshi Terauchi; Aikou Okamoto; Yumiko Wada; Ei Hasegawa; Toru Sasaki; Osamu Akutagawa; Yasukazu Sagawa; Hirotaka Nishi; Keiichi Isaka
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

Review 8.  Considerations in the surgical management of ovarian cancer in the elderly.

Authors:  Carrie Langstraat; William A Cliby
Journal:  Curr Treat Options Oncol       Date:  2013-03

9.  Complications and Outcomes of Diaphragm Surgeries in Epithelial Ovarian Malignancies.

Authors:  Amrita Datta; Ajit Sebastian; Rachel George Chandy; Vinotha Thomas; Dhanya Susan Thomas; Reka Karuppusami; Anitha Thomas; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2021-09-08

10.  Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer.

Authors:  P N J Pathiraja; R Garruto-Campanile; R Tozzi
Journal:  Int J Surg Oncol       Date:  2013-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.